Table 2
Antigens successfully detected on Immunohistowax processed mouse tissue sections
| Antigens | Clones | Specificity | Dilution | Sources |
|---|---|---|---|---|
| *Fusion protein; °synthesised hapten carrier protein. | ||||
| Ars, arsenate; BSA, bovine serum albumin; DC, dendritic cell; h, human; IFN-γ, interferon γ; Ig, immunoglobulin; IL, interleukin; L, ligand; MHC, major histocompatibility complex; MΦ, macrophage; NK, natural killer; PMN, polymorphonuclear cell; TCR, T cell receptor; VCAM, vascular cell adhesion molecule. | ||||
| CD2 | 12–15 | Cell adhesion molecule | 10–20 μg/ml | Southern Biotechnology Associates, Inc |
| CD3 | 7D6 | T cells | 20–30 μg/ml | Coulie and colleagues14 |
| CD4 | RM4–5 | T helper cells | 20 μg/ml | Pharmingen |
| CD8 | 53–6.7 | T cells | 20 μg/ml | Pharmingen |
| CD90/Thy 1.2 | 53–2.1 | T cells | 10–20 μg/ml | Pharmingen |
| TCRαβ | H57–597 | T cells (TCR) | 20–30 μg/ml | Pharmingen |
| TCRγδ | 13D5 | T cells (TCR) | 20–30 μg/ml | Peterman and colleagues15 |
| TCR Vβ8 | F23.2 | T cells (TCR) | 20 μg/ml | ATCC |
| TCR Vβ6 | 44.22.1 | T cells (TCR) | 20 μg/ml | Payne and colleagues16 |
| B220/CD45R | RA3–6B2 | B cells | 5–10 μg/ml | Pharmingen |
| IgD | LoMD6 | B cells | 5–10 μg/ml | Lefebvre and colleagues17 |
| IgM | LoMM9 | B cells | 5–10 μg/ml | Lefebvre and colleagues17 |
| MHC-II | 14.4.4 | B cells, DC, Mφ | 5–10 μg/ml | ATCC |
| CD11c | N418 | Mainly DC | 5–10 μg/ml | Metlay and colleagues18 |
| CD11c | HL3 | Mainly DC | 5–10 μg/ml | Pharmingen |
| CD11b/Mac-1 | M1/70 | MΦ | 5–10 μg/ml | Pharmingen |
| NK | 5E6 | NK cells | 10–20 μg/ml | Pharmingen |
| Pan-NK | DX5 | NK cells | 10–20 μg/ml | Pharmingen |
| Ly-6G/GR1 | RB6–8C5 | Granulocytes | 10–20 μg/ml | Pharmingen |
| PMN antigen | 7/4 | Neutrophils | 10–20 μg/ml | Caltag |
| CD40 | 3/23 | B cells, DC, Mφ | 10–20 μg/ml | Hasbold and colleagues19 |
| Intracytoplasmic granules | 2A1 | Mature DC | 5–10 μg/ml | Inaba and colleagues20 |
| Intracytoplasmic granules | M342 | Mature DC | Undiluted supernatant | Agger and colleagues21 |
| DEC-205 | NLDC-145 | Mature DC | 20–30 μg/ml | Kraal and colleagues22 |
| CD35 | 8C12 | CR1 (Follicular DC) | 5–10 μg/ml | Pharmingen |
| CD86/B7.2 | GL1 | Activated B cells, DC, Mφ | 10–20 μg/ml | Hathcock and colleagues23 |
| CD25 | 7D4 | Activated T cells, B cells, DC | 10–20 μg/ml | Pharmingen |
| Ly-77 | GL7 | Activated T cells, B cells | 10–20 μg/ml | Pharmingen |
| CD44 | 1M7 | Activated T cells | 10–20 μg/ml | Pharmingen |
| CD69 | H1.2F3 | Activated T cells | 10–20 μg/ml | Pharmingen |
| Phosphotyrosin | 4G10 | Activated cells | 20–30μg/ml | Upstate Biotechnology Incorporation |
| OX40 | mOX40L–hIgG1* | Activated T cells | 20–30μg/ml | Cantab Pharmaceutical Research Ltd |
| VCAM-1 | M/K-2 | Adhesion molecule | 10–20 μg/ml | R&D Systems |
| Anti-Ars Ig | Ars-BSA° | Ars specific B cells | 20 μg/ml | |
| IL-2 | S4B6 | Cytokine | 20–30 μg/ml | Pharmingen |
| IL-4 | 11B11 | Cytokine | 20–30 μg/ml | Pharmingen |
| INF-γ | Db1 | Cytokine | 20–30 μg/ml | Paineau and colleagues24 |
| IL-10 | JESS-2A5 | Cytokine | 20–30 μg/ml | Pharmingen |
